Naproxen kinetics in synovial fluid of patients with osteoarthritis.
作者信息
Bruno R, Iliadis A, Jullien I, Guego M, Pinhas H, Cunci S, Cano J P
机构信息
Recherche Syntex France, Leuville-sur-Orge.
出版信息
Br J Clin Pharmacol. 1988 Jul;26(1):41-4. doi: 10.1111/j.1365-2125.1988.tb03361.x.
Abstract
- The kinetics of naproxen in synovial fluid were studied in 407 osteoarthritic outpatients with knee effusion requiring aspiration, following a single 1100 mg oral dose of naproxen sodium. 2. The drug concentration-time profiles were described by a biexponential function. Naproxen entered synovial fluid rapidly, reaching a maximum concentration of 36 mg l-1 (Cmax) at 7.5 h. The first order input rate constant (kOs) was 0.41 +/- 0.15 h-1 with a lag time (tlag) of 0.24 +/- 0.36 h. 3. Elimination from the fluid was slow (t1/2 = 31 +/- 12 h) and appreciable drug concentrations were still measurable (27 mg l-1) after 24 h. 4. During once daily dosing of naproxen sodium, naproxen should accumulate in synovial fluid, a steady-state being achieved within a week of treatment. The predicted accumulation ratio based on trough concentration was 2.4.
摘要
相似文献
1
Naproxen kinetics in synovial fluid of patients with osteoarthritis.
Br J Clin Pharmacol. 1988 Jul;26(1):41-4. doi: 10.1111/j.1365-2125.1988.tb03361.x.
2
Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses.
Am J Vet Res. 1995 Aug;56(8):1075-80.
3
Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.
Eur J Clin Pharmacol. 1994;46(1):3-7. doi: 10.1007/BF00195907.
4
Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Clin Pharmacokinet. 2004;43(7):467-78. doi: 10.2165/00003088-200443070-00003.
5
[Serum, synovial and intra-articular pharmacokinetics of naproxen after one-gram oral administration in patients with rheumatoid polyarthritis].
Rev Rhum Mal Osteoartic. 1988 Apr 30;55(6):435-9.
6
Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.
J Rheumatol. 1995 Dec;22(12):2295-303.
7
Naproxen concentrations in serum, synovial fluid, and synovium.
Scand J Rheumatol. 1977;6(3):155-7. doi: 10.3109/03009747709095441.
8
Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats.
Biopharm Drug Dispos. 1997 Oct;18(7):623-33. doi: 10.1002/(sici)1099-081x(199710)18:7<623::aid-bdd46>3.0.co;2-v.
9
Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose.
Osteoarthritis Cartilage. 2007 Jul;15(7):764-72. doi: 10.1016/j.joca.2007.01.019. Epub 2007 Mar 13.
10
Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis.
Drugs. 1988;35 Suppl 1:46-51. doi: 10.2165/00003495-198800351-00010.
引用本文的文献
1
Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging.
Inflammopharmacology. 2025 Oct 11. doi: 10.1007/s10787-025-02001-8.
2
Naproxen treatment inhibits articular cartilage loss in a rat model of osteoarthritis.
J Orthop Res. 2021 Oct;39(10):2252-2259. doi: 10.1002/jor.24937. Epub 2020 Dec 15.
3
The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse.
Pharm Res. 2010 Jan;27(1):143-50. doi: 10.1007/s11095-009-9988-x. Epub 2009 Oct 30.
4
Clinical pharmacokinetics of naproxen.
Clin Pharmacokinet. 1997 Apr;32(4):268-93. doi: 10.2165/00003088-199732040-00002.
5
Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.
Eur J Clin Pharmacol. 1994;46(1):3-7. doi: 10.1007/BF00195907.
6
Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.
Clin Pharmacokinet. 1989 Sep;17(3):145-62. doi: 10.2165/00003088-198917030-00002.
7
Quantitative analysis of walking in patients with knee osteoarthritis: a method of assessing the effectiveness of non-steroidal anti-inflammatory treatment.
Ann Rheum Dis. 1990 Dec;49(12):990-3. doi: 10.1136/ard.49.12.990.
8
Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.
Drugs. 1990 Jul;40(1):91-137. doi: 10.2165/00003495-199040010-00006.
本文引用的文献
1
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
Drug Metab Rev. 1984;15(1-2):153-71. doi: 10.3109/03602538409015063.
2
Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics.
Clin Pharmacokinet. 1983 Nov-Dec;8(6):496-522. doi: 10.2165/00003088-198308060-00002.
3
Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects.
J Pharm Sci. 1972 May;61(5):703-8. doi: 10.1002/jps.2600610507.
4
Statistical estimations in pharmacokinetics.
J Pharmacokinet Biopharm. 1974 Apr;2(2):123-48. doi: 10.1007/BF01061504.
5
Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis.
Br J Clin Pharmacol. 1986 Feb;21(2):155-63. doi: 10.1111/j.1365-2125.1986.tb05170.x.
6
Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation.
Br J Clin Pharmacol. 1987 Feb;23(2):189-93. doi: 10.1111/j.1365-2125.1987.tb03028.x.
7
Steady-state dosage regimen calculations in linear pharmacokinetics.
Int J Biomed Comput. 1986 May;18(3-4):167-82. doi: 10.1016/0020-7101(86)90014-0.
8
Total and free ketoprofen in serum and synovial fluid after intramuscular injection.
Clin Pharmacol Ther. 1987 Nov;42(5):555-61. doi: 10.1038/clpt.1987.196.
9
Naproxen concentrations in serum, synovial fluid, and synovium.
Scand J Rheumatol. 1977;6(3):155-7. doi: 10.3109/03009747709095441.
Zotero 插件